Testing HK-660S for primary sclerosing cholangitis
Part of Digestive system clinical trials.
This trial tests a new drug, HK-660S, for people with primary sclerosing cholangitis (PSC), a liver disease that affects the bile ducts. It aims to see if the drug can improve liver health and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of PSC with high alkaline phosphatase (ALP) levels in your blood.
- You must not have other significant liver diseases, such as hepatitis or fatty liver disease.
- You must not have heavy alcohol use or certain medical conditions, like uncontrolled diabetes or severe heart disease.
- You must agree to use effective contraception if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
This trial tests if a fecal microbiota transplant (FMT) can help people with primary sclerosing cholangitis (PSC) and inactive inflammatory bowel disease (IBD). It compares FMT against a placebo to see if it improves liver health.
This trial tests a new type of stent (a small tube placed in bile ducts) that dissolves on its own over time in patients with primary sclerosing cholangitis (PSC), a rare disease affecting the bile ducts. The goal is to widen narrowed ducts and reduce the need for repeated procedures.
This study follows people diagnosed with primary sclerosing cholangitis to better understand the condition over time. It may help doctors learn which factors affect health and care, and improve future treatment decisions.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
Hear when a new Primary Sclerosing Cholangitis (PSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.